![](https://voice.ons.org//sites/default/files/2020-05/FDA-Update-700_11_6.jpg)
FDA Grants Accelerated Approval to Epcoritamab-Bysp for Relapsed or Refractory Follicular Lymphoma
On June 26, 2024, the U.S. Food and Drug Administration (FDA) granted accelerated approval to epcoritamab-bysp (Epkinly™), a bispecific CD20-directed CD3 T-cell engager, for adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.